pipette
ESEspañol

GC801-enabled AAV gene therapy in a neonate with Pompe disease

J. Chen, W. Ma, H. Qi, X. Ma, Y. He, L. He, Y. Ke, L. Zhuang, X. Jiang, J. Wang, J. Xu, Y. Xia, J. Zhou, Y. Wang, X. Dong, X. Wu, Z. Feng

PreprintReal-world use

In the authors' words

We report a neonate with IOPD who had high pre-existing anti-AAV9 antibody titers, which precluded eligibility for AAV9-mediated gene therapy (GC301). Preconditioning with a single dose of the IgG-degrading enzyme GC801 (0.2 mg/kg) safely reduced serum IgG from 6.25 g/L to a nadir of 0.72 g/L within 5 days. This pharmacological window facilitated successful GC301 vector transduction, driving a robust increase in GAA activity to 19.38 mmol/L/16h by day 84. Crucially, no adverse events beyond the underlying IOPD were observed. Our findings support the potential utility of GC801 as an agent to overcome pre-existing humoral barriers in neonatal gene therapy candidates.

Main resultThe abstract does not state a limitation.

Appeared: Wednesday, September 30. medRxiv. Preprint, not yet peer-reviewed.

DOI: 10.64898/2026.09.23.26363499